MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze TRLV →
    • FindStock Picks / Stock Screener
    • Value · TRLVIntrinsic Value Calculator
    • Invest · TRLVInvestment Case
    • Hold · TRLV5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
TRLV

TRLV

Trulieve Cannabis Corp.

$11.17
-0.44
 (-3.75%)
Exchange:  NYSE
Market Cap:  1.9B
Shares Outstanding:  191.3M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Drug Manufacturers – Specialty & GenericView industry performance
   
CEO:  Kimberly A. Rivers
Full Time Employees:  5000
Address: 
3494 Martin Hurst Road
Tallahassee
FL
32312
US
Website:  http://www.trulieve.com
Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
TRTRLV logoTRLVTrulieve Cannabis Corp.1.9B——-13.7%
ALALVO logoALVOAlvotech1.6B——3.6%
ANANIP logoANIPANI Pharmaceuticals, Inc.1.6B14.97.79.3%
PRPRGO logoPRGOPerrigo Company plc2.2B—7.23.3%
SUSUPN logoSUPNSupernus Pharmaceuticals, Inc.1.6B—9.8-2.7%
PAPAHC logoPAHCPhibro Animal Health Corporation1.5B15.811.811.8%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/08/07 — Q2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year2025
Revenue1,181,180
Gross Profit711,167
EBITDA328,329
Operating Income148,322
Net Income-116,381

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year2025
Total Assets2,696,098
Total Liabilities1,553,089
Total Stockholders Equity1,161,233
Total Debt563,623
Cash and Cash Equivalents255,535

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year2025
Operating Cash Flow272,821
Capital Expenditure-60,510
Free Cash Flow212,311
Net Income-122,248
Net Change in Cash15,825

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)976,833.100Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,014,645.184Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)991,600Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)281,586.100Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)288,066.085Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)284,116.588Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)101,302.915Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)106,422.103Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)103,302Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)368,189.283Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)382,441.466Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)373,755.244Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)0.540Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0.560Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)0.530Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
1.54
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-4.2
?Enterprise Value
 (TTM)
: 
2.001B  ?EV/FCF
 (TTM)
: 
10.71
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-44.03%  ?ROIC
 (TTM)
: 
-13.65%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.75
?P/B
 (TTM)
: 
2.58  ?Current Ratio
 (TTM)
: 
5.94

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates TRLV intrinsic value between $6.67 – $7.49 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate TRLV Intrinsic Value

Common questions about TRLV valuation

Is Trulieve Cannabis Corp. (TRLV) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Trulieve Cannabis Corp. (TRLV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is TRLV a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TRLV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is TRLV’s P/E ratio?

You can see TRLV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for TRLV?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is TRLV a good long-term investment?

Whether TRLV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Trulieve Cannabis Corp.

  • Trulieve Cannabis Corp. intrinsic value calculatorEstimate what the business is worth
  • Trulieve Cannabis Corp. 5-year outlookWhat has to go right, and what could go wrong
TRLV

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-3.75
MarketSnap

Trading Metrics:

Open: 11.6   Previous Close: 11.6
Day Low: 11.01   Day High: 11.68
Year Low: 4.62   Year High: 13.28
Price Avg 50: 11.21   Price Avg 200: 8.86
Volume: 940634   Average Volume: 1.496M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Trulieve Reports Third Quarter 2026 Results
05-11-2026 06:15
Trulieve Reports Third Quarter 2026 Results
Trulieve Cannabis Corp. (NYSE:TRLV) Short Interest Update
28-09-2026 03:52
Trulieve Cannabis Corp. (NYSE:TRLV) Short Interest Update
Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards
11-09-2026 13:04
Trulieve: As Regulatory Headwinds Wane, Value Creation Is On The Cards
Trulieve Reports Second Quarter 2026 Results
07-08-2026 06:15
Trulieve Reports Second Quarter 2026 Results
Trulieve Announces Planned Termination of Executive Automatic Securities Disposition Plan
26-06-2026 16:30
Trulieve Announces Planned Termination of Executive Automatic Securities Disposition Plan
Trulieve's NYSE Listing Is Historic. But Is the Stock Still Worth Buying?
22-06-2026 09:09
Trulieve's NYSE Listing Is Historic. But Is the Stock Still Worth Buying?

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze TRLV →
    • FindStock Picks / Stock Screener
    • Value · TRLVIntrinsic Value Calculator
    • Invest · TRLVInvestment Case
    • Hold · TRLV5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read